Coexistence of BCR::ABL1 translocation and JAK2V617F mutations in indian patients with myeloproliferative neoplasms: A case series
Authors:
Open Access
- 5 July 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Indian Journal of Pathology and Microbiology
- Vol. 68 (3) , 592-595
Abstract
BCR::ABL1 translocation and JAK2V617F mutations are canonical variants of myeloproliferative neoplasms (MPNs). Traditionally considered mutually exclusive, they may rarely coexist. We report the clinicopathological profile and treatment outcomes of four MPN patients with coexistence of these disease-defining genetic variants. Both mutations were detected simultaneously in three patients who did not harbor tell-tale signs of CML and were evaluated for both BCR::ABL1 and JAK2V617F based on clues from hemogram, peripheral-blood and bone-marrow examination. All were treated with imatinib and hydroxyurea and attained major molecular response after 2–7 months. In another patient, JAK2V617F was detected 15 years after the diagnosis of CML at the time of evaluation of loss of hematological and molecular response. She was treated with dasatinib but no hematologic or molecular response was attained after 6 months despite good compliance. In conclusion, BCR::ABL1 and JAK2V617F may rarely coexist in MPN with variable temporal evolution, clinicopathological profile, and treatment response.Keywords
This publication has 9 references indexed in Scilit:
- Co-occurrence of JAK2-V617 F mutation and BCR::ABL1 translocation in chronic myeloproliferative neoplasms: a potentially confounding genetic combinationFrontiers in Oncology, 2024
- JAK2 V617f in chronic myeloid leukemia: driving force or passive bystander?Hematology, 2022
- Sequential development of JAK2V617F and BCR-ABL1: a “double-hit” myeloproliferative neoplasm with morphologic transitionJournal of Hematopathology, 2021
- Emergence of BCR-ABL1 Chronic Myeloid Leukemia in a JAK2-V617F Polycythemia VeraJournal of Hematology, 2020
- Coexistence of BCR/ABL1 -positive chronic myeloid leukemia and JAK2 V617F -mutated myelofibrosis successfully treated with dasatinib and ruxolitinibBlood Research, 2019
- Myeloproliferative neoplasms with concurrent BCR–ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology groupLaboratory Investigation, 2018
- BCR-ABL and JAK2V617F Mutation Co-existence, Rare or Just UnexploredIndian Journal of Hematology and Blood Transfusion, 2017
- BCR‐ABL1‐positive and JAK2 V617F‐positive clones in 23 patients with both aberrations reveal biologic and clinical importanceBritish Journal of Haematology, 2016
- Concomitant occurrence of BCR-ABL and JAK2V617F mutationBlood, 2011